Related Experiment Video
Updated: Jan 8, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Statin Intolerance, Evolocumab for Hyperlipidemia, and Arrhythmia: Lessons Learnt From a Challenging Clinical
Matthew M Balocco1,2, Rockib Uddin3, Sara P Dimeo1,2,4
1Emergency Medicine, Creighton University School of Medicine, Phoenix, USA.
A patient on the PCSK9 inhibitor evolocumab developed new-onset atrial fibrillation (AF). This case highlights the importance of monitoring for rare cardiac events in complex patients undergoing PCSK9 inhibitor therapy.
Area of Science:
- Cardiology
- Pharmacology
Background:
- PCSK9 inhibitors like evolocumab are vital for patients intolerant to statins.
- A 78-year-old woman with extensive cardiovascular disease and statin intolerance required non-statin lipid therapy.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis IV: Nursing Management
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Myocarditis III: Medical Management

